The American Journal of Gastroenterology · 1999 · 61 citations · 22 references
PharmacyImmunologyInternal MedicineHepatic PharmacotherapyHepatitis PharmacotherapyHepatologyAntiviral TherapyInterferon ResponsesInterferon-based TherapyLiver DiseaseTreatment DurationViral HepatitisHepatitis B TherapyInterferon Alfa TherapyMedian AgeTotal Dose
Objective: The response rate to alpha interferon (IFN) of chronic anti-HBe–positive hepatitis B is variable. We studied whether type, dose, and schedule of IFN, and type and frequency of posttreatment monitoring, influence the response rate. Methods: Seventy-two consecutive anti-HBe–positive chronic hepatitis B patients (59 male and 13 female, median age 41 yr) stratified by sex and histology were randomly allocated to three treatment arms. Twenty-seven patients (A) received 10 million units alpha-N1 IFN i.m. t.w. for 24 wk (total dose: 720 million units); 21 (B) received 9 million units alpha-2a IFN i.m. t.w. for 4 wk, followed by 18 million units for 12 wk and 9 million units for 8 wk (972 million units); 24 (C) received 2 alpha-2a IFN courses (9 million units i.m. t.w. for 16 and 12 wk separated by a 6-month interval [756 million units]). Primary response was defined by normal ALT and serum HBV-DNA levels below 10 pg/ml at the end of therapy and sustained response by normal ALT (tested monthly), undetectable HBV-DNA and IgM anti-HBc (<7 I.U. Paul Ehrlich Institute) (tested every 3 months) during the posttreatment follow-up. Results: At the end of treatment, 12, 8, and 13 patients from groups A, B, and C, respectively, were responders. At the 18-month follow-up, two patients in group A and only one in groups B and C maintained the response. Overall, after 34 months (median posttreatment follow-up), three patients were long term responders, whereas three showed a sustained remission after relapse. Conclusions: The rate of long term response to interferon of anti-HBe–positive chronic hepatitis B is poor, independent of IFN type, dose, or schedule; the more stringent the monitoring, the higher the relapse rate.
22
Hiroaki Okamoto, S Yotsumoto, Y. Akahane et al. · Journal of Virology · 1990 · 518 citations · Full text
Stephanos J. Hadziyannis, Harvey M. Lieberman, Gerassimos Karvountzis et al. · Hepatology · 1983 · 397 citations